share_log

Windtree Enter Asset Purchase Agreement With Varian Biopharmaceuticals To Acquire Certain Of Its Assets, Including A Proprietary Atypical Protein Kinase C Iota Inhibitor

Moomoo 24/7 ·  Apr 8 16:51

The Company also completed a $1.5 million convertible note bridge financing. With successful development, the Company would pay up to $2.3 million in milestone payments upon the achievement of certain regulatory and clinical development milestones relating to the acquired assets with the Company having the option to pay such milestone payments either in cash or the Company's common stock.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment